Idorsia Ltd (IDIA) - Net Assets

Latest as of March 2026: CHF-1.18 Billion CHF ≈ $-1.49 Billion USD

Based on the latest financial reports, Idorsia Ltd (IDIA) has net assets worth CHF-1.18 Billion CHF (≈ $-1.49 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF480.46 Million ≈ $607.43 Million USD) and total liabilities (CHF1.66 Billion ≈ $2.09 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Idorsia Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF-1.18 Billion
% of Total Assets -244.88%
Annual Growth Rate N/A
5-Year Change -1191.29%
10-Year Change N/A
Growth Volatility 305.31

Idorsia Ltd - Net Assets Trend (2016–2025)

This chart illustrates how Idorsia Ltd's net assets have evolved over time, based on quarterly financial data. See Idorsia Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Idorsia Ltd (2016–2025)

The table below shows the annual net assets of Idorsia Ltd from 2016 to 2025. For live valuation and market cap data, see Idorsia Ltd market capitalisation.

Year Net Assets Change
2025-12-31 CHF-1.14 Billion
≈ $-1.44 Billion
+6.19%
2024-12-31 CHF-1.21 Billion
≈ $-1.53 Billion
-25.13%
2023-12-31 CHF-968.72 Million
≈ $-1.22 Billion
-46.56%
2022-12-31 CHF-660.96 Million
≈ $-835.63 Million
-734.29%
2021-12-31 CHF104.20 Million
≈ $131.74 Million
-82.20%
2020-12-31 CHF585.48 Million
≈ $740.21 Million
+256.25%
2019-12-31 CHF164.35 Million
≈ $207.78 Million
-75.01%
2018-12-31 CHF657.62 Million
≈ $831.42 Million
-11.07%
2017-12-31 CHF739.51 Million
≈ $934.94 Million
+45.58%
2016-12-31 CHF507.97 Million
≈ $642.21 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Idorsia Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 318332800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock CHF12.54 Million %
Other Components CHF2.37 Billion %
Total Equity CHF-1.14 Billion 100.00%

Idorsia Ltd Competitors by Market Cap

The table below lists competitors of Idorsia Ltd ranked by their market capitalization.

Company Market Cap
Varroc Engineering Limited
NSE:VARROC
$1.03 Billion
Ningbo Donly Co Ltd
SHE:002164
$1.03 Billion
Sarawak Oil Palms Bhd
KLSE:5126
$1.03 Billion
LegalZoom.com Inc
NASDAQ:LZ
$1.03 Billion
Kunshan Top A Intelligent Equipment
SHE:300836
$1.03 Billion
Accel Entertainment Inc
NYSE:ACEL
$1.03 Billion
Lecron Energy Saving Materials
SHE:300343
$1.03 Billion
Sam Hwa Capaci
KO:001820
$1.03 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Idorsia Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -1,212,145,000 to -1,137,173,000, a change of 74,972,000.
  • Net loss of 112,000,000 reduced equity.
  • Share repurchases of 84,428,000 reduced equity.
  • New share issuances of 84,428,000 increased equity.
  • Other comprehensive income decreased equity by 2,859,000.
  • Other factors increased equity by 189,831,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CHF-112.00 Million -9.85%
Share Repurchases CHF84.43 Million -7.42%
Share Issuances CHF84.43 Million +7.42%
Other Comprehensive Income CHF-2.86 Million -0.25%
Other Changes CHF189.83 Million +16.69%
Total Change CHF- %

Book Value vs Market Value Analysis

This analysis compares Idorsia Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 CHF4.24 CHF4.51 x
2017-12-31 CHF6.45 CHF4.51 x
2018-12-31 CHF5.26 CHF4.51 x
2019-12-31 CHF1.30 CHF4.51 x
2020-12-31 CHF4.10 CHF4.51 x
2021-12-31 CHF0.62 CHF4.51 x
2022-12-31 CHF-3.73 CHF4.51 x
2023-12-31 CHF-5.43 CHF4.51 x
2024-12-31 CHF-6.64 CHF4.51 x
2025-12-31 CHF-5.30 CHF4.51 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Idorsia Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -50.68%
  • • Asset Turnover: 0.47x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-109.73%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 -65.42% 0.00% 0.00x 1.79x CHF-386.37 Million
2017 -1.91% -9.03% 0.12x 1.73x CHF-88.81 Million
2018 -58.13% -637.42% 0.04x 2.12x CHF-452.86 Million
2019 -286.85% -2076.70% 0.02x 5.82x CHF-511.89 Million
2020 -76.03% -620.31% 0.05x 2.45x CHF-503.67 Million
2021 -608.99% -1795.23% 0.02x 14.23x CHF-645.02 Million
2022 0.00% -852.60% 0.11x 0.00x CHF-761.80 Million
2023 0.00% -195.50% 0.30x 0.00x CHF-201.05 Million
2024 0.00% -234.43% 0.22x 0.00x CHF-142.54 Million
2025 0.00% -50.68% 0.47x 0.00x CHF1.72 Million

Industry Comparison

This section compares Idorsia Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $461,766,364
  • Average return on equity (ROE) among peers: -38.19%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Idorsia Ltd (IDIA) CHF-1.18 Billion -65.42% N/A $1.03 Billion
Addex Therapeutics Ltd (ADXN) $16.93 Million -91.05% 0.33x $6.98 Million
Bachem Holding AG (BANB) $365.36 Million 11.28% 0.36x $5.20 Billion
BB Biotech AG (BION) $3.29 Billion -12.31% 0.11x $2.48 Billion
Bioversys AG (BIOV) $10.68 Million -175.24% 2.27x $161.41 Million
Basilea Pharmaceutica AG (BSLN) $210.24 Million 51.16% 0.51x $686.09 Million
MINDMAZE THERAPEUTICS HOLDING SA (MMTX) $38.34 Million -25.84% 0.34x $49.96 Million
Molecular Partners AG (MOLN) $151.79 Million -0.10% 0.45x $145.86 Million
Newron Pharmaceuticals SpA (NWRN) $36.80 Million -54.91% 0.64x $297.11 Million
Relief Therapeutics Holding AG (RLF) $36.66 Million -46.69% 0.45x $36.33 Million

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.45 Billion
CHF1.14 Billion CHF
Market Cap Rank
#8973 Global
#119 in Switzerland
Share Price
CHF4.51
Change (1 day)
-3.10%
52-Week Range
CHF1.87 - CHF4.79
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more